Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vanda Pharmaceuticals (VNDA) Net Income towards Common Stockholders (2016 - 2025)

Historic Net Income towards Common Stockholders for Vanda Pharmaceuticals (VNDA) over the last 17 years, with Q4 2025 value amounting to -$141.2 million.

  • Vanda Pharmaceuticals' Net Income towards Common Stockholders fell 277518.32% to -$141.2 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$220.5 million, marking a year-over-year decrease of 106663.14%. This contributed to the annual value of -$220.5 million for FY2025, which is 106652.91% down from last year.
  • Vanda Pharmaceuticals' Net Income towards Common Stockholders amounted to -$141.2 million in Q4 2025, which was down 277518.32% from -$22.6 million recorded in Q3 2025.
  • In the past 5 years, Vanda Pharmaceuticals' Net Income towards Common Stockholders registered a high of $9.6 million during Q2 2021, and its lowest value of -$141.2 million during Q4 2025.
  • For the 5-year period, Vanda Pharmaceuticals' Net Income towards Common Stockholders averaged around -$9.9 million, with its median value being -$1.1 million (2023).
  • Its Net Income towards Common Stockholders has fluctuated over the past 5 years, first surged by 185646.26% in 2021, then crashed by 305777.78% in 2024.
  • Quarter analysis of 5 years shows Vanda Pharmaceuticals' Net Income towards Common Stockholders stood at $7.1 million in 2021, then fell by 2.96% to $6.9 million in 2022, then tumbled by 134.71% to -$2.4 million in 2023, then tumbled by 105.44% to -$4.9 million in 2024, then tumbled by 2775.18% to -$141.2 million in 2025.
  • Its last three reported values are -$141.2 million in Q4 2025, -$22.6 million for Q3 2025, and -$27.2 million during Q2 2025.